1. Home
  2. KSCP vs ENTX Comparison

KSCP vs ENTX Comparison

Compare KSCP & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Knightscope Inc.

KSCP

Knightscope Inc.

HOLD

Current Price

$2.95

Market Cap

58.1M

ML Signal

HOLD

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.29

Market Cap

62.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KSCP
ENTX
Founded
2013
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
58.1M
62.6M
IPO Year
2022
2015

Fundamental Metrics

Financial Performance
Metric
KSCP
ENTX
Price
$2.95
$1.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$17.00
$9.00
AVG Volume (30 Days)
470.2K
96.2K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
63.54
N/A
EPS
N/A
0.07
Revenue
$11,335,000.00
$42,000.00
Revenue This Year
$218.66
N/A
Revenue Next Year
$54.32
N/A
P/E Ratio
N/A
$17.43
Revenue Growth
4.91
N/A
52 Week Low
$2.52
$0.91
52 Week High
$10.13
$3.22

Technical Indicators

Market Signals
Indicator
KSCP
ENTX
Relative Strength Index (RSI) 46.09 54.59
Support Level $2.52 $1.17
Resistance Level $4.50 $1.37
Average True Range (ATR) 0.23 0.07
MACD 0.03 -0.00
Stochastic Oscillator 62.01 65.00

Price Performance

Historical Comparison
KSCP
ENTX

About KSCP Knightscope Inc.

Knightscope Inc is a security technology company based in Silicon Valley. It designs, develops, manufactures, markets, and supports Autonomous Security Robots (ASRs), autonomous charging stations, the proprietary Knightscope Security Operations Center software user interface, Emergency Communication Devices platform with real-time on-site data collection and analysis and a proprietary interface for both indoor and outdoor usage. In addition, it developed and operates the Knightscope Security Operations Center (KSOC) which allows real-time data access, a service accessible to all its clients.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: